Bridgebio Oncology Therapeutics, Inc. (BBOT)
1.82
-0.04
(-2.15%)
USD |
NASDAQ |
Nov 20, 10:47
Bridgebio Oncology Therapeutics Cash from Investing (Quarterly) : 50.34M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 50.34M |
| June 30, 2026 | 45.73M |
| March 31, 2026 | -285.41M |
| December 31, 2025 | 7.766M |
| September 30, 2025 | 65.56M |
| June 30, 2025 | 9.639M |
| Date | Value |
|---|---|
| March 31, 2025 | 15.37M |
| December 31, 2024 | 25.56M |
| September 30, 2024 | 37.91M |
| June 30, 2024 | 0.00 |
| March 31, 2024 | -184.00M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | -0.231M |
| IRulya Therapeutics, Inc. | -67.79M |
| PepGen Inc. | 12.46M |
| Q32 Bio, Inc. | -0.052M |
| Oncolytics Biotech, Inc. | -0.0069M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -28.36M |
| Cash from Financing (Quarterly) | 0.442M |
| Free Cash Flow | -151.03M |
| Free Cash Flow Per Share (Quarterly) | -0.3539 |
| Free Cash Flow to Equity (Quarterly) | -28.24M |
| Free Cash Flow to Firm (Quarterly) | -28.38M |
| Free Cash Flow Yield | -103.4% |